Prostate Cancer Podcast Series
The Xofigo®▼ (radium-223 dichloride) series
Description
Xofigo, radium-223 dichloride, a treatment that has been indicated for the treatment of eligible men with metastatic castration-resistant prostate cancer (mCRPC) for over 10 years. So, what is its role in today’s clinical practice? Listen to our 20-minute podcasts below to hear from multidisciplinary experts in prostate cancer.
Access each podcast episode below as well as a short reflective learning guide developed to empower your learning. Each learning guide includes:
- Key learning points for each podcast.
- Reflective learning questions to best improve the learnings from each episode and to aid application of knowledge.
- A certificate of completion.
Episode 1 – Why treat with Xofigo?
Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible mCRPC patients in their clinics.
Dr Omi ParikhConsultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group.
Ellie CradockLead Molecular Radiotherapy Manager at the University Hospitals Bristol NHS Foundation Trust.
Optimising patient identification & referral
Hear from the perspective of both a leading oncologist and nuclear medicine consultant how they optimise the treatment and referral pathway for their patients.
Dr Julia MurrayConsultant clinical oncologist at The Royal Marsden NHS Foundation Trust and an honorary clinical senior lecturer at The Institute of Cancer Research, London, specialising in radiotherapy and systemic therapy for prostate cancer.
Dr Amy EcclesConsultant Radionuclide Radiologist and Clinical Lead for Nuclear Medicine at Imperial College Healthcare NHS Trust, London.
The Practicalities of treatment
Gain valuable insights from leading healthcare professionals as they discuss what it means practically for the treating physicians, the multidisciplinary team and patients when going on treatment with radium-223 dichloride.
Dr Yeepei SongConsultant in Clinical Oncology at The Christie Hospital.
Dr Maryam JessopChief Nuclear Medicine Technologist at Brighton and Sussex University Hospitals.
PP-XOF-GB-0461 | February 2024